“Long-Term Safety and Effectiveness of Adalimumab for Moderat-to-Severe Psoriasis: Results from the Eight-Year Interim Analysis of the ESPIRIT Registry”. SKIN The Journal of Cutaneous Medicine 1, no. 3.1 (October 27, 2017): s22. Accessed April 19, 2025. https://skin.dermsquared.com/skin/article/view/79.